Tracleer review

Tracleer, licensed by Actelion Pharmaceuticals, is a medication commonly used to treat people suffering from high blood pressure in the lungs, or Pulmonary Arterial Hypertension (PAH). This medication causes the arteries in the patients lungs to expand and contract to decrease the pressure. Despite its usefulness, Tracleer is known to cause liver problems. This medication is an edothelin receptor antagonist.

Endothelin is a natural substance in the human body that causes the blood vessels to narrow, which inadvertently increases the pressure commonly attributed to patients suffering from PAH. Tracleer is capable of stopping the actions of Endothelin and reduces the pressure on these vessels. Tracleer may also be used on patients suffering from chronic heart failure.

Tracleer is taken orally twice a day before or after meals. The standard dosage for Tracleer is 62.5mg for a 4-week treatment. The doctor's prescription might increase the dosage to 125mg for maintenance. Doctors limit the usage of Tracleer due to its side-effects. The medication is known to cause liver problems - especially when higher dosages are given to patients. Also, prolonged use of 125mg of Tracleer might increase the risk of liver abnormalities.

According to studies, 8 out of 165 patients using 125mg Tracleer after the 4-week treatment are observed to have abnormal liver functions. The majority of patients taking this medication suffer from cephalalgia, nasopharyngitis, flushing, hepatic abnormal functions, lower-limb edema, abnormally low blood pressure, and frequent abnormality of heartbeats.

Other side effects commonly experienced by patients taking Tracleer include Dyspepsia, Edema, lethargy or weaknesses, Pruritus andAnemia.

A low percentage of patients using Tracleer may suffer rashes, hypersensitivity, thrombocytopenia, anemia, and jaundice.

Large plasma concentration is seen to occur when Tracleer is used along with CYP2C9 and CYP3A4 inhibitors. Such medications under these families include fluconazole, ketoconazole, itraconazole, ritonavir, amprevanir, erythromycin, and dilitiazem.

Studies show that hormonal contraceptives may not have the desired results when used in conjunction with Tracleer. It was observed that hormonal contraceptives, both oral and injectable, have decreased effectiveness (to as low as 66%) when paired with Tracleer.

It is highly recommended to consult your doctor before taking Tracleer. Due to the high risk of liver abnormalities attributed to this medication, experts advise a thorough medical and physical examination to avoid harmful side effects during and after treatment.

It was also observed that treatment using Tracleer causes an abnormal decrease in a patient's hemoglobin and hematocrit count. Patients undergoing Tracleer treatment should have their hemoglobin and hematocrit levels carefully monitored during the treatment and three months after the procedure.

Tracleer has the following structural formula:

Chemical structure of tracleer

• Molecular formula of tracleer is C27H29N5O6S
• Chemical IUPAC Name is N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl-pyrimidin-4-yl]-4-tert-butyl-benzenesulfonamide
• Molecular weight is 551.615 g/mol
Tracleer available : 62.5mga tablets and 125mg tablets

Generic name: Bosentan

  Your Tracleer review